CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Close

Method for screening anticancer substances, set or kit for implementing said method

Reference

86825-01

Patents status

French patent application BF0551616 filed on juin 14th, 2005 and entitled “Technique de criblage fonctionnel de molécules bioactives anti-métastasiques sur cellules épithéliales invasives”

Inventors

Pierre ROUX
Marion DE TOLEDO

commercial status

Licensed

Laboratory

Centre de Recherche de Biochimie Macromoléculaire (CRBM), a CNRS laboratory (UMR5237), in Montpellier, France.

Description

TECHNICAL DESCRIPTION

The inventors have developed a new method for screening anticancer substances. This protocol is based on the colon cancer model cells SW620 and the observation that neoformation of E-cadherin type junctions is in correlation with metastases reduction.

This protocol includes the following steps:

  • obtaining a culture of tumoral cells not expressing E-cadherin on their cell membrane
  • contacting the cells obtained at step a) with a candidate substance or a combination of candidate substances
  • detecting, in the culture of cells obtained at the end of step b), the presence of E-cadherin at the cell surface
  • positively selecting the candidate substance or combination of candidate substances when E-cadherin has been detected at step c).

INDUSTRIAL APPLICATIONS

Screening of new anticancer molecules especially anti-metastatic molecules.

An important advantage of this new method is to reduce the cost and the delay in new therapeutic molecules screening.
Drug screening for developing anti-metastatic therapy protocols.

For further information, please contact us (Ref 86825-01)

Need further information ?

Contact us
Close

Contact us

  • This field is for validation purposes and should be left unchanged.
Close

Newest patents